Literature DB >> 1791075

Cephalosporins--cefotaxime 10 years later, a major drug with continued use.

H C Neu1.   

Abstract

Cefotaxime has in the past decade proved to be a most useful agent. It has established the efficacy and safety suggested in the early in vitro, pharmacological and clinical papers. It remains an excellent agent to treat many community and hospital-acquired respiratory infections, urinary tract infections, meningitis, particularly in pediatrics, spontaneous bacterial peritonitis and selected abdominal and gynecological infections.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1791075     DOI: 10.1007/bf01715770

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  31 in total

Review 1.  Third-generation cephalosporins in the treatment of rare infections.

Authors:  R G Finch
Journal:  Am J Med       Date:  1990-04-09       Impact factor: 4.965

2.  Antibiotics for penetrating abdominal trauma: a prospective comparative trial of single agent cephalosporin therapy versus combination therapy.

Authors:  B A Bivins; L Crots; F N Obeid; V J Sorensen; H M Horst; J J Fath
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Jan-Feb       Impact factor: 2.803

Review 3.  Extended-spectrum beta-lactamases.

Authors:  A Philippon; R Labia; G Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

4.  Comparative in vitro activity of cefoxitin, cefotaxime alone, and in combination with desacetylcefotaxime against the Bacteroides species.

Authors:  H N Canawati
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Jan-Feb       Impact factor: 2.803

5.  Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia.

Authors:  J P Sculier; J Klastersky
Journal:  Am J Med       Date:  1984-03       Impact factor: 4.965

6.  The pharmacokinetics of new cephalosporins: significance in clinical practice.

Authors:  H C Neu
Journal:  Bull N Y Acad Med       Date:  1984-05

Review 7.  Third generation cephalosporins: safety profiles after 10 years of clinical use.

Authors:  H C Neu
Journal:  J Clin Pharmacol       Date:  1990-05       Impact factor: 3.126

Review 8.  Empiric therapy of severe infections in adults.

Authors:  J Modai
Journal:  Am J Med       Date:  1990-04-09       Impact factor: 4.965

9.  Genetic control of beta-lactamase production in Enterobacter cloacae.

Authors:  G Korfmann; B Wiedemann
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

Review 10.  beta-Lactam antibiotics: structural relationships affecting in vitro activity and pharmacologic properties.

Authors:  H C Neu
Journal:  Rev Infect Dis       Date:  1986 Jul-Aug
View more
  3 in total

1.  Decision analysis modelling of costs and outcomes following cefepime monotherapy in Canada.

Authors:  M T Halpern; R E Brown; M Drolet; S V Sorensen; L A Mandell
Journal:  Can J Infect Dis       Date:  1997-01

2.  Cefotaxime desensitization.

Authors:  G Papakonstantinou; J R Bogner; F Hofmeister; R Hehlmann
Journal:  Clin Investig       Date:  1993-02

Review 3.  Adverse effects of newer cephalosporins. An update.

Authors:  J W Thompson; R F Jacobs
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.